Although chemotherapy is amongst the few treatments for cancer, there are numerous side effects associated with therapy. Chemotherapy-induced myelosuppression is one such common complication of cancer treatment that could not only limit dosage but also prove potentially fatal for cancer patients. Chemotherapy-induced myelosuppression is a condition wherein the ability of the bone marrow to produce blood cells is decreased. There have been various attempts to minimize chemotherapy-induced myelosuppression, which have not been very effective. This has triggered the need for innovating and developing more effective chemotherapy-induced myelosuppression treatment. Pharmaceutical companies are working towards bringing new therapeutics that could help in boosting the capabilities in the chemotherapy-induced myelosuppression treatment.
New Investments Aimed at Addressing Chemotherapy-Induced Myelosuppression Treatment Requirements
While cancer reflects growth, the chemotherapy-induced myelosuppression conditions are also expected to come along with the cancer therapeutics, thereby creating need for effective chemotherapy-induced myelosuppression treatment. Investments remain a crucial factor that helps boost the chemotherapy-induced myelosuppression treatment. For instance, a recognized developer of off-the-shelf and universal cell therapies for critical diseases, Nohla Therapeutics closed a Series B financing of about $45 million. The company plans to utilize the proceeds for the completion of the ongoing Phase 2 trials of the dilanubicel, which is a major candidate in chemotherapy-induced myelosuppression and allogeneic transplant. Moreover, these proceedings are intended to be used for the commercial manufacturing and Phase 3 trial needs. It would allow Nohla Therapeutics to contribute their ongoing progress in advancing their product, dilanubicel towards potential regulatory approvals in several regions. Such investments are expected to boost the chemotherapy-induced myelosuppression treatment potential across the globe.
Pharmaceutical Companies Bullish over New Therapeutics
The pharmaceutical companies conduct various trials that help gauge the efficacy of certain drugs for the chemotherapy-induced myelosuppression treatment. With several developments hitting the chemotherapy-induced myelosuppression treatment landscape with respect to the clinical trials, the pharmaceutical companies are gaining major profitability over time.
For instance, Trilaciclib by G1 Therapeutics, a biopharmaceutical company, is a chemotherapy-induced myelosuppression treatment which appeared to reduce chemotherapy-induced myelosuppression in small cell lung cancer. During the clinical trials, it was witnessed that the cancer patients undergoing first-line therapy for extensive-stage small cell lung cancer could well tolerate trilaciclib. The clinical trial data demonstrated clear evidence that this chemotherapy-induced myelosuppression treatment could help in preserving the immune system function and bone marrow from the side effects of chemotherapy. With positive myelopreservation results gained from two randomized trials, the company plans to request meetings with regulatory agencies of the US and Europe in early 2019 to discuss the factors studies during clinical trials and the potential approval for their treatment.
Adjuvant Therapy for Cancer Management to Gain Popularity
Adjuvant cancer therapies are used to enhance and foster the effect of primary cancer therapies in eliminating or minimizing the burden of cancer on the body, thereby help prevent cancer recurrence and boost survival of patients. Adjuvant therapy is gaining major significance in cancer management. In line with this, there are several new therapies introduced that are further gaining a nod from regulatory bodies, simplifying chemotherapy-induced myelosuppression treatment. For instance, Myelo Therapeutics GmbH, a leading pharmaceutical company that develops innovative therapeutics for chemotherapy-induced myelosuppression treatment and others, was recently granted an Organ Drug Designation from the US FDA for its new chemical offering, Myelo001, designed to treat Acute Radiation Syndrome. Myelo001 is a revolutionary and clinical-stage adjuvant cancer therapy for the radiotherapy- and chemotherapy-induced myelosuppression treatment. With this FDA approval, Myelo Therapeutics is able to open new possibilities in the chemotherapy-induced myelosuppression treatment landscape, with respect to adjuvant therapy.
The ongoing research and development in chemotherapy-induced myelosuppression treatment are expected to trigger new innovations over the years. To know more about the key developments carried out by pharmaceutical companies providing chemotherapy-induced myelosuppression treatment, click here.